Prognostic	B:C0220901
implications	O
of	O
the	O
intrinsic	O
molecular	O
subtypes	O
in	O
male	O
breast	I:C0238033
cancer	I:C0238033
.	O

Prognostic	O
implications	O
of	O
the	O
intrinsic	O
molecular	O
subtypes	O
in	O
male	B:C0238033
breast	I:C0238033
cancer	I:C0238033
.	O

Intrinsic	B:C0022885
molecular	I:C0022885
subtyping	I:C0022885
has	O
been	O
widely	O
used	O
in	O
female	O
breast	I:C0007104
cancer	I:C0007104
,	O
and	O
it	O
has	O
proven	O
its	O
significance	O
.	O

Intrinsic	O
molecular	I:C0022885
subtyping	I:C0022885
has	O
been	O
widely	O
used	O
in	O
female	B:C0007104
breast	I:C0007104
cancer	I:C0007104
,	O
and	O
it	O
has	O
proven	O
its	O
significance	O
.	O

In	O
this	O
article	B:C1706852
,	O
we	O
aimed	O
to	O
study	O
the	O
intrinsic	O
subtypes	O
of	O
male	O
breast	I:C0238033
cancer	I:C0238033
(	O
male	O
breast	I:C0238033
cancer	I:C0238033
)	O
in	O
correlation	O
with	O
clinicopathological	O
features	I:C1301651
.	O

In	O
this	O
article	O
,	O
we	O
aimed	O
to	O
study	B:C2603343
the	O
intrinsic	O
subtypes	O
of	O
male	O
breast	I:C0238033
cancer	I:C0238033
(	O
male	O
breast	I:C0238033
cancer	I:C0238033
)	O
in	O
correlation	O
with	O
clinicopathological	O
features	I:C1301651
.	O

In	O
this	O
article	O
,	O
we	O
aimed	O
to	O
study	O
the	O
intrinsic	O
subtypes	O
of	O
male	B:C0238033
breast	I:C0238033
cancer	I:C0238033
(	O
male	O
breast	I:C0238033
cancer	I:C0238033
)	O
in	O
correlation	O
with	O
clinicopathological	O
features	I:C1301651
.	O

In	O
this	O
article	O
,	O
we	O
aimed	O
to	O
study	O
the	O
intrinsic	O
subtypes	O
of	O
male	O
breast	I:C0238033
cancer	I:C0238033
(	O
male	B:C0238033
breast	I:C0238033
cancer	I:C0238033
)	O
in	O
correlation	O
with	O
clinicopathological	O
features	I:C1301651
.	O

In	O
this	O
article	O
,	O
we	O
aimed	O
to	O
study	O
the	O
intrinsic	O
subtypes	O
of	O
male	O
breast	I:C0238033
cancer	I:C0238033
(	O
male	O
breast	I:C0238033
cancer	I:C0238033
)	O
in	O
correlation	O
with	O
clinicopathological	B:C1301651
features	I:C1301651
.	O

We	O
retrospectively	O
identified	O
130	O
male	B:C0238033
breast	I:C0238033
cancer	I:C0238033
cases	O
from	O
2004	O
to	O
2013	O
.	O

Intrinsic	O
molecular	O
subtypes	O
were	O
determined	O
by	O
immunohistochemistry	B:C0021044
(	O
immunohistochemistry	O
)	O
.	O

Intrinsic	O
molecular	O
subtypes	O
were	O
determined	O
by	O
immunohistochemistry	O
(	O
immunohistochemistry	B:C0021044
)	O
.	O

From	O
a	O
total	O
of	O
130	O
male	B:C0238033
breast	I:C0238033
cancer	I:C0238033
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	I:C3642345
subtype	I:C3642345
,	O
44.6	O
%	O
were	O
luminal	O
B	I:C3642346
,	O
5	O
%	O
were	O
HER2	O
positive	I:C1960398
and	O
5	O
%	O
were	O
triple	O
negative	I:C1513916
tumors	O
.	O

From	O
a	O
total	O
of	O
130	O
male	O
breast	I:C0238033
cancer	I:C0238033
cases	O
,	O
45.4	O
%	O
of	O
tumors	B:C0027651
were	O
luminal	O
A	I:C3642345
subtype	I:C3642345
,	O
44.6	O
%	O
were	O
luminal	O
B	I:C3642346
,	O
5	O
%	O
were	O
HER2	O
positive	I:C1960398
and	O
5	O
%	O
were	O
triple	O
negative	I:C1513916
tumors	O
.	O

From	O
a	O
total	O
of	O
130	O
male	O
breast	I:C0238033
cancer	I:C0238033
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	B:C3642345
A	I:C3642345
subtype	I:C3642345
,	O
44.6	O
%	O
were	O
luminal	O
B	I:C3642346
,	O
5	O
%	O
were	O
HER2	O
positive	I:C1960398
and	O
5	O
%	O
were	O
triple	O
negative	I:C1513916
tumors	O
.	O

From	O
a	O
total	O
of	O
130	O
male	O
breast	I:C0238033
cancer	I:C0238033
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	I:C3642345
subtype	I:C3642345
,	O
44.6	O
%	O
were	O
luminal	B:C3642346
B	I:C3642346
,	O
5	O
%	O
were	O
HER2	O
positive	I:C1960398
and	O
5	O
%	O
were	O
triple	O
negative	I:C1513916
tumors	O
.	O

From	O
a	O
total	O
of	O
130	O
male	O
breast	I:C0238033
cancer	I:C0238033
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	I:C3642345
subtype	I:C3642345
,	O
44.6	O
%	O
were	O
luminal	O
B	I:C3642346
,	O
5	O
%	O
were	O
HER2	B:C1960398
positive	I:C1960398
and	O
5	O
%	O
were	O
triple	O
negative	I:C1513916
tumors	O
.	O

From	O
a	O
total	O
of	O
130	O
male	O
breast	I:C0238033
cancer	I:C0238033
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	I:C3642345
subtype	I:C3642345
,	O
44.6	O
%	O
were	O
luminal	O
B	I:C3642346
,	O
5	O
%	O
were	O
HER2	O
positive	I:C1960398
and	O
5	O
%	O
were	O
triple	B:C1513916
negative	I:C1513916
tumors	O
.	O

From	O
a	O
total	O
of	O
130	O
male	O
breast	I:C0238033
cancer	I:C0238033
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	I:C3642345
subtype	I:C3642345
,	O
44.6	O
%	O
were	O
luminal	O
B	I:C3642346
,	O
5	O
%	O
were	O
HER2	O
positive	I:C1960398
and	O
5	O
%	O
were	O
triple	O
negative	I:C1513916
tumors	B:C0027651
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
immunohistochemistry	B:C0021044
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	I:C0475440
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	I:C1516974
(	I:C1516974
ER	I:C1516974
)	I:C1516974
status	I:C1516974
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	I:C1514471
(	I:C1514471
PR	I:C1514471
)	I:C1514471
status	I:C1514471
(	O
p=0.001	O
)	O
,	O
HER2	O
status	I:C1512413
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
immunohistochemistry	O
intrinsic	O
subtypes	O
regarding	O
tumor	B:C0475440
size	I:C0475440
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	I:C1516974
(	I:C1516974
ER	I:C1516974
)	I:C1516974
status	I:C1516974
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	I:C1514471
(	I:C1514471
PR	I:C1514471
)	I:C1514471
status	I:C1514471
(	O
p=0.001	O
)	O
,	O
HER2	O
status	I:C1512413
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
immunohistochemistry	O
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	I:C0475440
(	O
p=0.001	O
)	O
,	O
estrogen	B:C1516974
receptor	I:C1516974
(	I:C1516974
ER	I:C1516974
)	I:C1516974
status	I:C1516974
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	I:C1514471
(	I:C1514471
PR	I:C1514471
)	I:C1514471
status	I:C1514471
(	O
p=0.001	O
)	O
,	O
HER2	O
status	I:C1512413
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
immunohistochemistry	O
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	I:C0475440
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	I:C1516974
(	I:C1516974
ER	I:C1516974
)	I:C1516974
status	I:C1516974
(	O
p=0.001	O
)	O
,	O
progesterone	B:C1514471
receptor	I:C1514471
(	I:C1514471
PR	I:C1514471
)	I:C1514471
status	I:C1514471
(	O
p=0.001	O
)	O
,	O
HER2	O
status	I:C1512413
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
immunohistochemistry	O
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	I:C0475440
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	I:C1516974
(	I:C1516974
ER	I:C1516974
)	I:C1516974
status	I:C1516974
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	I:C1514471
(	I:C1514471
PR	I:C1514471
)	I:C1514471
status	I:C1514471
(	O
p=0.001	O
)	O
,	O
HER2	B:C1512413
status	I:C1512413
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
immunohistochemistry	O
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	I:C0475440
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	I:C1516974
(	I:C1516974
ER	I:C1516974
)	I:C1516974
status	I:C1516974
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	I:C1514471
(	I:C1514471
PR	I:C1514471
)	I:C1514471
status	I:C1514471
(	O
p=0.001	O
)	O
,	O
HER2	O
status	I:C1512413
(	O
p=0.001	O
)	O
and	O
Ki67	B:C0208804
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

The	O
distribution	O
of	O
breast	B:C0006142
cancer	I:C0006142
intrinsic	O
subtypes	O
in	O
males	O
is	O
different	O
compared	O
to	O
its	O
female	O
counterpart	O
;	O
however	O
,	O
they	O
do	O
n't	O
seem	O
to	O
give	O
the	O
same	O
prognostic	O
value	I:C0220901
.	I:C0220901

The	O
distribution	O
of	O
breast	O
cancer	I:C0006142
intrinsic	O
subtypes	O
in	O
males	O
is	O
different	O
compared	O
to	O
its	O
female	O
counterpart	O
;	O
however	O
,	O
they	O
do	O
n't	O
seem	O
to	O
give	O
the	O
same	O
prognostic	B:C0220901
value	I:C0220901
.	I:C0220901

